Inactive Instrument

Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Airbus, BP, Merck, Pfizer, Meta... Our Logo
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl DJ
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Biotechnology Index CI
Merck Completes Acceleron Pharma Acquisition MT
Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share MT
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Composite Index CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Global BMI Index CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P TMI Index CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Biotechnology Select Industry Index CI
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc CI
Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro Capital Advisors LLC, Holocene Advisors, LP, Darwin Global Management Limited and others for $7.1 billion. CI
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offer MT
Merck Extends Tender Offer for Acceleron Pharma MT
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95 MT
Merck Extends FTC Review Period for Acceleron Buyout MT
Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of $160 Million MT
Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 30, 2021 CI
Merck : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisition MT
Merck : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Company MT
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron RE
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron RE
Merck : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share MT
ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target MT
Chart Acceleron Pharma Inc.
More charts
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.
More about the company
  1. Stock
  2. Equities
  3. Stock Acceleron Pharma Inc. - Nasdaq
  4. News Acceleron Pharma Inc.
  5. Acceleron Pharma : Oppenheimer Adjusts Acceleron Pharma PT to $141 From $140, Maintains Outperform Rating